Summary
This article gives an overview of the most important classes of drugs used for each system (e.g., the cardiovascular system), as well as the most common drugs that are used in the treatment of specific conditions (e.g., Parkinson disease).
Analgesics
Overview | |||||||||
---|---|---|---|---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | Contraindications | Interactions | ||||
Nonopioid analgesics | |||||||||
Nonsteroidal anti-inflammatory drugs (NSAIDs) | Ibuprofen, diclofenac, indomethacin, naproxen [1] |
|
|
|
|
|
|
| |
Aspirin [2] |
|
| |||||||
COX-2 inhibitors (selective NSAIDs, e.g., celecoxib) [3] |
|
|
| ||||||
Acetaminophen |
|
|
|
| |||||
Metamizole |
|
|
|
| |||||
Opioid analgesics | |||||||||
Low-potency opioids (e.g., codeine, tramadol) |
|
|
|
|
| ||||
Medium-potency opioids (e.g., morphine, oxycodone, methadone) | |||||||||
High-potency opioids (e.g., fentanyl, buprenorphine) |
Antimicrobial drugs
This section provides an overview of the most important antimicrobial drug classes and substances.
Antibiotics
Antifungals
Overview | ||||
---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | |
Polyenes (e.g., amphotericin B, nyastin) |
| |||
Azoles | Triazoles (e.g., fluconazole, itraconazole) | |||
Imidazoles (e.g., ketoconazole, clotrimazole) | ||||
Echinocandins (e.g., caspofungin) | ||||
Pyridone derivatives (ciclopirox) | ||||
Benzofurans (griseofulvin) | ||||
Antimetabolites (flucytosine) |
Antihelminthic drugs
Overview | |||
---|---|---|---|
Drug | Indications | Mechanism of action | Adverse effects |
Bendazoles (e.g., albendazole, mebendazole) |
| ||
Pyrantel pamoate | |||
Praziquantel | |||
Ivermectin | |||
Diethylcarbamazine |
Antimalarial drugs
Overview | |||
---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects |
Chloroquine |
| ||
Hydroxychloroquine | |||
Doxycycline/tetracycline | |||
Mefloquine | |||
Quinine | |||
Artemether-lumefantrine | |||
Atovaquone-proguanil | |||
Quinidine | |||
Primaquine |
Antiprotozoal drugs
Overview | |||
---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects |
Pentamidine |
| ||
Suramin | |||
Eflornithine | |||
Nifurtimox | |||
Melarsoprol | |||
Sodium stibogluconate | |||
Paromomycin | |||
Miltefosine | |||
Diloxanide | |||
Iodoquinol |
Antivirals
Hepatitis viruses
Overview | ||||
---|---|---|---|---|
Agents | Mechanism of action | Indications | Adverse effects | |
Antivirals against both hepatitis B and C | ||||
| ||||
Antivirals against hepatitis B | ||||
Nucleotide analogs (e.g., tenofovir, adefovir) |
| |||
Nucleoside analogs (e.g., entecavir, lamivudine) | ||||
Antivirals against hepatitis C | ||||
Guanosine analogs (e.g., ribavirin) |
| |||
Direct-acting antivirals (DAAs) | NS3/4A protease inhibitors (e.g., simeprevir, grazoprevir) | |||
Nonnucleoside NS5A polymerase inhibitors (e.g., ledipasvir, ombitasvir) | ||||
NS5B inhibitors (e.g., dasabuvir, sofosbuvir) |
Herpes viruses
Overview | ||||
---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | |
Acyclovir, valacyclovir |
| |||
Ganciclovir, valganciclovir | ||||
Cidofovir | ||||
Pyrophosphate analogs (e.g., foscarnet) | ||||
Antisense oligonucleotides (e.g., fomivirsen) |
Influenza viruses
Overview | |||
---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects |
| |||
Neuraminidase inhibitors (e.g., oseltamivir, zanamivir) | |||
RNA polymerase endonuclease inhibitor (baloxavir marboxil) |
Ectoparasiticides
Overview | |||
---|---|---|---|
Drug | Indications | Mechanism of action | Adverse effects |
Permethrin |
| ||
Dimeticone | |||
Malathion |
Biologics
Cardiovascular drugs
This section provides an overview of the most important drug classes and substances targeting the cardiovascular system.
Antiarrhythmics
Overview | ||||||
---|---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | Contraindications | Interactions | |
Sodium channel blockers (class I) | Class IA (e.g., quinidine, procainamide) |
|
|
| ||
Class IB (e.g., lidocaine, phenytoin) |
|
| ||||
Class IC (e.g., propafenon) |
| |||||
Beta blockers (class II; e.g., metoprolol, propranolol) |
|
| ||||
Potassium channel blockers (class III; e.g., amiodarone) [8] |
| |||||
Calcium channel blockers (class IV; diltiazem, verapamil) |
|
| ||||
Ivabradine |
|
|
|
|
| |
Adenosine |
|
|
|
| ||
Magnesium sulfate [9] |
|
|
|
| ||
Digoxin |
|
|
|
|
Antihypertensives
Lipid-lowering agents
Overview | ||||||
---|---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | Contraindications | Interactions | |
Statins (e.g., atorvastatin, simvastatin) |
| |||||
Fibrates (e.g., bezafibrate, fenofibrate, gemfibrozil) | ||||||
Niacin | ||||||
PCSK9 inhibitors (e.g., alirocumab, evolocumab) | ||||||
Marine omega-3 fatty acids (fish oil) | ||||||
Central and peripheral nervous system drugs
This section provides an overview of the most important drug classes and substances that act on the central and peripheral nervous system.
Anesthetics
Overview | |||||
---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | ||
Intravenous anesthetics | |||||
Propofol |
| ||||
Barbiturates | |||||
Benzodiazepines | |||||
Inhalational anesthetics | |||||
Nitrous oxide |
| ||||
Desflurane | |||||
Sevoflurane | |||||
Isoflurane | |||||
Enflurane | |||||
Halothane | |||||
Methoxyflurane | |||||
Local anesthetics | |||||
Ester group anesthetics | Short-acting (e.g., procaine) |
| |||
Long-acting (e.g., tetracaine) | |||||
Amide group anesthetics | Intermediate-acting (e.g., lidocaine) | ||||
Long-acting (e.g., bupivacaine) |
Anticonvulsants
Overview | ||||||
---|---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | Contraindications | Interactions | |
First-generation (classic) anticonvulsants | Valproate |
| ||||
Carbamazepine | ||||||
Ethosuximide | ||||||
Phenytoin/fosphenytoin | ||||||
Phenobarbital | ||||||
Benzodiazepines | ||||||
Second-generation (newer) anticonvulsants | Lamotrigine [16] |
| ||||
Tiagabine [17] | ||||||
Levetiracetam [18] | ||||||
Pregabalin | ||||||
Vigabatrin [19] | ||||||
Topiramate [20] |
Antidepressants and mood stabilizers
Antiparkinson drugs
Overview | |||||
---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | ||
Dopamine precursors (L-DOPA) |
| ||||
Nonergot (e.g., ropinirole, pramipexole, apomorphine) | |||||
Ergot (bromocriptine) | |||||
NMDA antagonists (amantadine) | |||||
MAO-B inhibitors (e.g., rasagiline, selegiline) | |||||
Anticholinergic drugs (muscarinic antagonists; e.g., benztropine, biperiden) |
Antipsychotics
Overview | ||||
---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | |
First-generation antipsychotics (FGAs) | Low-potency antipsychotics (e.g., chlorpromazine) |
|
|
|
High-potency antipsychotics (e.g., haloperidol, fluphenazine) | ||||
Second-generation antipsychotics (SGAs; e.g., clozapine, olanzapine, risperidone) |
Glaucoma drugs
Overview | ||||
---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | |
Drugs that decrease the synthesis of aqueous humor | ||||
Beta blockers (e.g., timolol, betaxolol, carteolol) |
| |||
Alpha-1 agonists (e.g., epinephrine) | ||||
Alpha-2 agonists (e.g., apraclonidine, brimonidine) | ||||
Drugs that improve the outflow of aqueous humor | ||||
PGF2α (e.g., latanoprost, bimatoprost) |
| |||
Parasympathomimetics | Direct parasympathomimetics (e.g., pilocarpine, carbachol) | |||
Indirect parasympathomimetics (e.g., physostigmine, echothiophate) |
Muscle relaxants
Overview | ||||
---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | |
Parenteral muscle relaxants | ||||
Depolarizing muscle relaxants (succinylcholine) |
| |||
Nondepolarizing muscle relaxants | Short-acting nondepolarizing muscle relaxants (e.g., mivacurium) | |||
Intermediate-acting nondepolarizing muscle relaxants (e.g., rocuronium, atracurium, vecuronium) | ||||
Long-acting nondepolarizing muscle relaxants (e.g., pancuronium, tubocurarine) | ||||
Oral muscle relaxants | ||||
Tizanidine |
| |||
Baclofen | ||||
Dantrolene | ||||
Cyclobenzaprine | ||||
Oral benzodiazepines (e.g., diazepam, clonazepam) |
Sedative-hypnotic drugs
Overview | |||||||
---|---|---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | Contraindications | Interactions | ||
Benzodiazepines | Short-acting (e.g., midazolam, triazolam, alprazolam, oxazepam) |
| |||||
Intermediate-acting (e.g., temazepam, lorazepam) | |||||||
Long-acting (e.g., diazepam, clonazepam) | |||||||
Benzodiazepine-like substances (Z-drugs; e.g., zolpidem, zaleplon, eszopiclone) | |||||||
Barbiturates | Ultra short duration of action (e.g., thiopental) | ||||||
Short duration of action (e.g., pentobarbital) | |||||||
Intermediate duration of action (e.g., amobarbital) | |||||||
Long duration of action | Phenobarbital | ||||||
Primidone | |||||||
Melatonin agonists (e.g., ramelteon) | |||||||
Orexin antagonists (e.g., suvorexant) |
Chemotherapeutic drugs and detoxifying agents
Contraceptive methods
Overview | |||||||
---|---|---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | ||||
Hormonal contraception | |||||||
Oral contraceptive pill | Progestin-only contraceptive pills (POPs; minipill) |
|
|
| |||
| |||||||
Contraceptive patch |
| ||||||
Injectable progestin |
|
| |||||
Progestin intrauterine device | |||||||
Subdermal progestin implant | |||||||
Nonhormonal contraception | |||||||
Nonhormonal intrauterine device |
|
|
|
| |||
Behavioral methods | Coitus interruptus |
|
|
| |||
| |||||||
|
| ||||||
|
| ||||||
Barrier methods | Spermicides |
|
| ||||
Diaphragm |
| ||||||
Cervical cap |
| ||||||
|
| ||||||
|
| ||||||
Surgical sterilization | Vasectomy |
|
|
| |||
Female sterilization |
|
| |||||
Emergency contraception | |||||||
Hormonal methods |
| ||||||
Antiprogestins (e.g., ulipristal acetate) | |||||||
Ethinyl estradiol PLUS levonorgestrel (Yuzpe regimen) | |||||||
Nonhormonal methods (copper-containing intrauterine devices) |
|
Diuretics
Overview | |||
---|---|---|---|
Agents | Indications | ||
Osmotic agents (e.g., mannitol, urea) |
| ||
Carbonic anhydrase inhibitors (e.g., acetazolamide) [22] | |||
Thiazide diuretics (e.g., hydrochlorothiazide) | |||
Loop diuretics | Sulfonamides (e.g., furosemide) [23] | ||
Ethacrynic acid [24] | |||
Potassium-sparing diuretics | Aldosterone receptor antagonists (spironolactone, eplerenone) [25] | ||
Epithelial sodium channel blockers (triamterene, amiloride) |
Endocrine drugs
This section provides an overview of the most important drug classes and substances targeting the endocrine system.
Antidiabetics
Hypothalamic/pituitary gland drugs
Overview | |||
---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects |
ADH antagonists (vaptans, e.g., tolvaptan, conivaptan) |
| ||
ADH analogs (e.g., desmopressin, terlipressin) | |||
Oxytocin | |||
Somatostatin analogs (e.g., octreotide) | |||
GnRH agonists (e.g., goserelin leuprolide, nafarelin) | |||
GnRH antagonists (e.g., degarelix) | |||
GHRH analogs (e.g., tesamorelin) | |||
GH receptor antagonists (e.g., pegvisomant) |
Miscellaneous endocrine drugs
Overview | |||||
---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | ||
Sevelamer |
| ||||
Cinacalcet |
|
| |||
Cation-exchange medications | Resins (e.g., sodium polystyrene sulfonate) |
|
|
| |
Polymers (e.g., patiromer) | |||||
Fludrocortisone |
|
| |||
Demeclocycline |
|
|
Reproductive system drugs
Overview | ||||
---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | |
Selective estrogen receptor modulators (SERMs; e.g., tamoxifen, raloxifene, clomiphene) |
| |||
Synthetic estrogens (e.g., ethinyl estradiol, mestranol, diethylstilbestrol) | ||||
Aromatase inhibitors (e.g., anastrozole, letrozole, exemestane) | ||||
Cyproterone | ||||
Spironolactone | ||||
Ketoconazole | ||||
Anabolic steroids (e,g., methyltestosterone) | ||||
Progestins (e.g., levonorgestrel, medroxyprogesterone) | ||||
Antiprogestins (e.g., mifepristone, ulipristal) |
Thyroid drugs
Overview | |||||
---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | Contraindications | Interactions |
Antithyroid drugs | |||||
Thionamides (e.g., carbimazole, propylthiouracil) |
|
|
| ||
Potassium iodides (e.g., Lugol iodine) |
|
| |||
Hormone replacement drugs | |||||
Synthetic T4 (e.g., levothyroxine) |
|
|
|
| |
Synthetic T3 (e.g., liothyronine) |
Gastrointestinal drugs
Gout drugs
Overview | |||||||
---|---|---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | Contraindications | Interactions | ||
Acute gout flare | |||||||
Glucocorticoids (e.g., prednisone) |
|
|
|
|
| ||
NSAIDs (e.g., naproxen) |
| ||||||
Colchicine |
|
|
|
| |||
Chronic gout | |||||||
Xanthine oxidase inhibitors (XOIs) | Allopurinol |
|
|
|
|
| |
Febuxostat |
|
|
| ||||
Uricosurics (e.g., probenecid) |
|
|
|
|
| ||
Recombinant uricase (pegloticase) |
|
|
|
|
Hematologic drugs
Antiplatelet agents | |||||
---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | Contraindications | Interactions |
Irreversible cyclooxgenase inhibitors (aspirin) |
|
| Warfarin, NSAIDs: ↑ risk of bleeding [28][29] | ||
P2Y12 receptor antagonists (e.g., clopidogrel, ticagrelor, ticlopidine) |
|
|
| ||
Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) |
| GpIIb/IIIa inhibitors bind to and block gpIIb/IIIa receptors on the surface of activated platelets → inhibition of platelet aggregation and thrombus formation |
|
Oral anticoagulants | |||||||
---|---|---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | Contraindications | Interactions | ||
Vitamin K antagonists (coumarins, e.g., phenprocoumon, warfarin) |
|
|
|
|
|
| |
Direct oral thrombin inhibitors (e.g., dabigatran) |
|
|
|
| |||
Direct oral factor Xa inhibitors (e.g., apixaban, rivaroxaban) [30] |
|
|
|
Parenteral anticoagulants | ||||||
---|---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | Contraindications | Interactions | |
Unfractionated heparin (UFH |
|
|
|
|
|
|
Low molecular weight heparin (LMWH; e.g., enoxaparin, dalteparin) |
|
|
| |||
Synthetic heparin (fondaparinux) [32] |
|
|
|
| ||
Heparinoids (glycosaminoglycans, e.g., danaparoid) |
|
|
| |||
Direct thrombin inhibitors (e.g., argatroban, dabigatran) |
|
|
Fibrinolytics | ||||||
---|---|---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | Contraindications | Interactions | |
Fibrin-specific agents | Tissue plasminogen activator (tPA) |
|
|
|
| |
Recombinant plasminogen activators (rtPAs; e.g., alteplase, reteplase) | ||||||
Nonfibrin-specific agents (e.g., streptokinase, urokinase) |
Immunosuppressants
Overview | ||||
---|---|---|---|---|
Agents | Indications | Mechanism of action | Adverse effects | |
Glucocorticoids (e.g., prednisolone, hydrocortisone, dexamethasone) |
| |||
Calcineurin inhibitors | Cyclosporine A | |||
Tacrolimus | ||||
mTOR inhibitors (e.g., sirolimus, everolimus) | ||||
Purine analog (e.g., azathioprine) | ||||
IMDH/IMPDH inhibitors (e.g., mycophenolate mofetil) | ||||
Other cytostatic and antiproliferative agents (e.g., MTX, cyclophosphamide) | ||||
Protein drugs | Antibodies (e.g., basiliximab) | |||
Other biological proteins (e.g., etanercept) |